Opentrons Raises $40M Series E to Standardize Autonomous AI Science
As artificial intelligence accelerates drug discovery, Opentrons has secured $40 million to ensure physical laboratories can keep pace with AI-generated experiments.
As artificial intelligence models increasingly generate novel drug candidates and complex experimental protocols, the physical execution of these tests has become a major bottleneck. To bridge this gap, New York-based Opentrons has raised $40 million in Series E funding led by healthcare investor Avego, with participation from BroadOak Capital Partners.
Opentrons develops robotic systems and AI software designed to automate manual laboratory workflows. Its flagship platform, Opentrons Flex, combines physical lab robots with an AI-native software layer, allowing researchers to convert AI-generated experimental designs directly into automated, executable tasks without writing code.
Unlike legacy lab automation systems that require specialized engineering to program and operate, the startup relies on an open-source architecture and intuitive interfaces. The company has already deployed over 11,000 robots across 80 countries, serving major pharmaceutical firms and academic institutions.
The new capital will be used to expand the company's AI capabilities and data infrastructure. As the biotech industry shifts toward autonomous science, standardizing the physical execution of AI-driven research is critical to turning digital discoveries into real-world medical breakthroughs.
INTELLIGENCE BRIEF
WHY IT MATTERS
While AI can design millions of potential molecules in seconds, testing them still requires slow, manual lab work. Opentrons bridges this digital-to-physical divide, enabling true autonomous science.
WHO IS INVOLVED
Opentrons CEO James Atwood, Avego Managing Partner James Flexner, and BroadOak Capital Partners.
MARKET IMPACT
The convergence of AI and physical lab automation is creating a new paradigm for drug discovery. By standardizing robotic execution, Opentrons is positioning itself as the foundational operating system for the biotech industry's automated future.
This story was drafted with AI assistance and reviewed by TurkSpark editors before publication. Facts, figures, and names may be inaccurate — verify important details independently.
Showpad Founder's VC Firm Entourage Closes €100M Second Fund to Back European Deeptech
Read
Ex-Palantir Engineers Launch Dream with $17M from a16z to Bring AI World Models to Construction
Read